113 related articles for article (PubMed ID: 38472116)
1. Not All Binding Sites Are Equal: Site Determination and Folding State Analysis of Gas-Phase Protein-Metallodrug Adducts.
Eade L; Sullivan MP; Allison TM; Goldstone DC; Hartinger CG
Chemistry; 2024 May; 30(28):e202400268. PubMed ID: 38472116
[TBL] [Abstract][Full Text] [Related]
2. Characterizing activation mechanisms and binding preferences of ruthenium metallo-prodrugs by a competitive binding assay.
Artner C; Holtkamp HU; Hartinger CG; Meier-Menches SM
J Inorg Biochem; 2017 Dec; 177():322-327. PubMed ID: 28739166
[TBL] [Abstract][Full Text] [Related]
3. The interactions of the ruthenium(II)-cymene complexes with lysozyme and cytochrome c.
Stanic-Vucinic D; Nikolic S; Vlajic K; Radomirovic M; Mihailovic J; Cirkovic Velickovic T; Grguric-Sipka S
J Biol Inorg Chem; 2020 Mar; 25(2):253-265. PubMed ID: 32020293
[TBL] [Abstract][Full Text] [Related]
4. High-resolution crystal structures of a "half sandwich"-type Ru(II) coordination compound bound to hen egg-white lysozyme and proteinase K.
Chiniadis L; Bratsos I; Bethanis K; Karpusas M; Giastas P; Papakyriakou A
J Biol Inorg Chem; 2020 Jun; 25(4):635-645. PubMed ID: 32266561
[TBL] [Abstract][Full Text] [Related]
5. Interactions of arene ruthenium metallaprisms with human proteins.
Paul LE; Therrien B; Furrer J
Org Biomol Chem; 2015 Jan; 13(3):946-53. PubMed ID: 25410522
[TBL] [Abstract][Full Text] [Related]
6. Mass spectrometry and metallomics: A general protocol to assess stability of metallodrug-protein adducts in bottom-up MS experiments.
Michelucci E; Pieraccini G; Moneti G; Gabbiani C; Pratesi A; Messori L
Talanta; 2017 May; 167():30-38. PubMed ID: 28340724
[TBL] [Abstract][Full Text] [Related]
7. Reactions of a tetranuclear Pt-thiosemicarbazone complex with model proteins.
Marzo T; Navas F; Cirri D; Merlino A; Ferraro G; Messori L; Quiroga AG
J Inorg Biochem; 2018 Apr; 181():11-17. PubMed ID: 29353085
[TBL] [Abstract][Full Text] [Related]
8. Initial Protein Unfolding Events in Ubiquitin, Cytochrome c and Myoglobin Are Revealed with the Use of 213 nm UVPD Coupled to IM-MS.
Theisen A; Black R; Corinti D; Brown JM; Bellina B; Barran PE
J Am Soc Mass Spectrom; 2019 Jan; 30(1):24-33. PubMed ID: 29949061
[TBL] [Abstract][Full Text] [Related]
9. Stability of an organometallic ruthenium-ubiquitin adduct in the presence of glutathione: relevance to antitumour activity.
Hartinger CG; Casini A; Duhot C; Tsybin YO; Messori L; Dyson PJ
J Inorg Biochem; 2008 Dec; 102(12):2136-41. PubMed ID: 18834634
[TBL] [Abstract][Full Text] [Related]
10. Efficiently detecting metallodrug-protein adducts: ion trap versus time-of-flight mass analyzers.
Meier SM; Babak MV; Keppler BK; Hartinger CG
ChemMedChem; 2014 Jul; 9(7):1351-5. PubMed ID: 24643974
[TBL] [Abstract][Full Text] [Related]
11. Hydrolytic behaviour and chloride ion binding capability of [Ru(η6-p-cym)(H2O)3]2+: a solution equilibrium study.
Bíró L; Farkas E; Buglyó P
Dalton Trans; 2012 Jan; 41(1):285-91. PubMed ID: 22051630
[TBL] [Abstract][Full Text] [Related]
12. The aqueous stability and interactions of organoruthenium compounds with serum proteins, cell culture medium, and human serum.
Riisom M; Eade L; Tremlett WDJ; Hartinger CG
Metallomics; 2022 Jul; 14(7):. PubMed ID: 35751650
[TBL] [Abstract][Full Text] [Related]
13. Mapping Protein Structural Evolution upon Unfolding.
Avadhani VS; Mondal S; Banerjee S
Biochemistry; 2022 Feb; 61(4):303-309. PubMed ID: 35085435
[TBL] [Abstract][Full Text] [Related]
14. Exploring metallodrug-protein interactions by mass spectrometry: comparisons between platinum coordination complexes and an organometallic ruthenium compound.
Casini A; Gabbiani C; Michelucci E; Pieraccini G; Moneti G; Dyson PJ; Messori L
J Biol Inorg Chem; 2009 Jun; 14(5):761-70. PubMed ID: 19288144
[TBL] [Abstract][Full Text] [Related]
15. Water-soluble Ru(II)- and Ru(III)-halide-PTA complexes (PTA=1,3,5-triaza-7-phosphaadamantane): Chemical and biological properties.
Battistin F; Scaletti F; Balducci G; Pillozzi S; Arcangeli A; Messori L; Alessio E
J Inorg Biochem; 2016 Jul; 160():180-8. PubMed ID: 26920229
[TBL] [Abstract][Full Text] [Related]
16. Molecular mass spectrometry in metallodrug development: a case of mapping transferrin-mediated transformations for a ruthenium(III) anticancer drug.
Jarosz M; Matczuk M; Pawlak K; Timerbaev AR
Anal Chim Acta; 2014 Dec; 851():72-7. PubMed ID: 25440667
[TBL] [Abstract][Full Text] [Related]
17. Bipyrimidine ruthenium(II) arene complexes: structure, reactivity and cytotoxicity.
Betanzos-Lara S; Novakova O; Deeth RJ; Pizarro AM; Clarkson GJ; Liskova B; Brabec V; Sadler PJ; Habtemariam A
J Biol Inorg Chem; 2012 Oct; 17(7):1033-51. PubMed ID: 22791215
[TBL] [Abstract][Full Text] [Related]
18. Collision induced unfolding of protein ions in the gas phase studied by ion mobility-mass spectrometry: the effect of ligand binding on conformational stability.
Hopper JT; Oldham NJ
J Am Soc Mass Spectrom; 2009 Oct; 20(10):1851-8. PubMed ID: 19643633
[TBL] [Abstract][Full Text] [Related]
19. Screening organometallic binuclear thiosemicarbazone ruthenium complexes as potential anti-tumour agents: cytotoxic activity and human serum albumin binding mechanism.
Demoro B; de Almeida RF; Marques F; Matos CP; Otero L; Costa Pessoa J; Santos I; Rodríguez A; Moreno V; Lorenzo J; Gambino D; Tomaz AI
Dalton Trans; 2013 May; 42(19):7131-46. PubMed ID: 23519281
[TBL] [Abstract][Full Text] [Related]
20. Conformation of DNA modified by monofunctional Ru(II) arene complexes: recognition by DNA binding proteins and repair. Relationship to cytotoxicity.
Novakova O; Kasparkova J; Bursova V; Hofr C; Vojtiskova M; Chen H; Sadler PJ; Brabec V
Chem Biol; 2005 Jan; 12(1):121-9. PubMed ID: 15664521
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
